Opinion|Videos|March 12, 2025
The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC
Panelists discuss how recent data from KEYNOTE-671, AEGEAN, and CheckMate 77T reinforce neoadjuvant therapy’s efficacy in early-stage non–small cell lung cancer (NSCLC), showing consistent survival benefits. In contrast, adjuvant data remain conflicting, limiting its role. Neoadjuvant therapy should be prioritized, with adjuvant therapy reserved for select high-risk patients.
Advertisement
Video content above is prompted by the following:
- What are your perspectives on the latest efficacy, safety data, and recent approvals in early-stage NSCLC treatment, and how have these influenced your clinical practice?
- KEYNOTE-671: Wakelee H, et al. NEJM. 2023;389:491-503.
- AEGEAN: Heymach JV, et al. WCLC 2024. Abs OA13.03. (Approval August 2024)
- CheckMate 77T: Spicer J, et al. ESMO 2024. LBA50(Approval October 2024)
- Briefly comment on the conflicting data in the adjuvant setting and contrast that with the consistency demonstrated in the neoadjuvant setting, and discuss how you translate this into your clinical practice.
- Should neoadjuvant therapy be recommended for all patients who do not proceed directly to surgery?
- In which patients should adjuvant therapy be added, and what is the remaining role for adjuvant therapy alone?
Advertisement
Related to this article
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The MHLW approval covers all lines of therapy, including first-line use, in unresectable advanced or recurrent HER2-mutant NSCLC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 8/23
3
First-Line Ivonescimab Plus Chemotherapy Meets OS End Point in Advanced Biliary Tract Cancer
4
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
5